



## Tes Pharma Announces Formation of AKI Clinical Advisory Board

*Solomeo-Corciano (PG), Italy, January 21, 2025* – Tes Pharma, a biotech company focused on delivering first-in class therapeutics for high unmet medical needs in oncology, renal and metabolic diseases, today announced the formation of its Clinical Advisory Board (CAB) for the Acute Kidney Injury (AKI) program. The CAB, which includes internationally renowned experts in AKI, will provide scientific, clinical, and strategic guidance for the development of TES-AKI-01, our lead candidate for the treatment of AKI.

AKI is a common and critical condition characterized by a sudden decline in kidney function, with as many as 100 million cases occurring worldwide annually. Early intervention and effective prevention strategies are crucial to improve patient outcomes and reduce the long-term impact on kidney health.

Our Clinical Advisory Board comprises:

**Professor Giuseppe Remuzzi, MD**, is the Director of the Mario Negri Institute for Pharmacological Research and “Chiara Fama” Professor of Nephrology, University of Milan. Member of the Consiglio Superiore di Sanità and former Chief of Nephrology at the Bergamo Hospital and former President of the International Society of Nephrology (ISN). Prof. Remuzzi was honored by the Italian President of the Republic with the title of Cavaliere di Gran Croce in 2022.

**Professor John A. Kellum, MD, MCCM** is a Distinguished Professor of Critical Care Medicine, Medicine, Bioengineering and Clinical and Translational Science and holds an Endowed Chair in Critical Care Research from the University of Pittsburgh. He is also Chief Medical Officer for Spectral Medical, a late-stage medical device company developing diagnostics and therapeutics for sepsis.

**Professor Vincenzo Cantaluppi, MD**, is the Director of Nephrology and Kidney Transplantation Unit at the "Maggiore della Carità" University Hospital in Novara, Italy. He is Vice-Chair of the ERAKI Working Group of the European Renal Association (ERA), member of the international expert working group ADQI (Acute Disease Quality Initiative), founder and of the AKI and CRRT Project Group of the Italian Society of Nephrology (SIN), member of the joint commission SIN-SITO (Italian Society for Organ Transplantation) and SIN-SIAARTI (Italian Society of Analgesia, Anesthesia and Critical Care).

*“We are thrilled to convene a world-class Clinical Advisory Board for our AKI program,”* said Luca Benatti, Chief Executive Officer at Tes Pharma. *“They will bring unrivaled experience and knowledge that will be crucial in steering our clinical development program and ensuring the success of our new drug, TES-AKI-01.”*



### **About TES-AKI-01**

TES-AKI-01 is a potent and selective first in-class inhibitor of the  $\alpha$ -Amino- $\beta$ -Carboxymuconic- $\epsilon$ -Semiaaldehyde Decarboxylase (ACMSD) enzyme. ACMSD represents a branch point in the de novo NAD<sup>+</sup> biosynthesis pathway. Dysregulation of de novo NAD<sup>+</sup> biosynthesis with a consequent NAD<sup>+</sup> decline may occur in kidneys, liver in various pathological conditions such as Acute Kidney Injury (AKI), MASH and acute inflammation respectively. NAD<sup>+</sup> replenishment by kidney/liver-specific de novo biosynthesis recovers essential cellular pathways, such as mitochondrial dysfunction and compromised energetic state. Treatment with TES-AKI-01 recovers NAD<sup>+</sup> levels caused by increased energy demands in renal pathophysiological conditions, protecting the kidney from injury and promoting its recovery and functionality.

### **About Tes Pharma**

Tes Pharma is a biotech company focused on delivering first-in-class therapeutics for high unmet medical needs in oncology, renal and metabolic diseases. Tes Pharma's clinically validated drug discovery engine generates rationally designed drug candidates for novel targets. Tes Pharma has a long-standing partnership with Intercept/Alfasigma for the discovery and development of bile acid derivatives for the treatment of metabolic diseases. INT-787 is undergoing Phase 2 clinical studies for the treatment of severe alcohol hepatitis. TES-AKI-01 and TES-ONC-07 are two first-in-class small molecules for the treatment of acute kidney injury and for cancer immunotherapy, respectively, entering IND-enabling studies. Tes Pharma has an undisclosed pipeline of additional projects in the early phase of drug discovery.

For more information, please visit [www.tespharma.com](http://www.tespharma.com) or connect with the Company on [LinkedIn](#)

For further information, please contact:

Sara Malincarne

[smalincarne@tespharma.com](mailto:smalincarne@tespharma.com)

[www.tespharma.com](http://www.tespharma.com)